Search results for "Atypical"

showing 10 items of 111 documents

A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depress…

2017

Abstract Background Early Improvement of depressive symptoms within two weeks of antidepressant treatment is a highly sensitive but less specific predictor of later treatment outcome. The aim of this study was to identify clinical features at treatment initiation which are associated with early improvement and non-improvement as well as to identify variables predicting non-remission in patients showing an early improvement. Methods 889 patients with a major depressive episode according to DSM-IV who had participated in an antidepressant treatment trial served as study sample. Clinical predictors (demographic variables, psychopathology, comorbid disorders) were analysed in 698 (79%) early im…

AdultMalemedicine.medical_specialtyComorbidityAvoidant personality disorderPatient ReadmissionSeverity of Illness IndexSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsRating scaleInternal medicinemedicineHumansMajor depressive episodePsychiatryAtypical depressionDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptombusiness030217 neurology & neurosurgeryPsychopathologyJournal of Affective Disorders
researchProduct

Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. …

2009

Combining measurements of the monoamine metabolites in the cerebrospinal fluid (CSF) and neuroimaging can increase efficiency of drug discovery for treatment of brain disorders. To address this question, we examined five drug-naive patients suffering from schizophrenic disorder. Patients were assessed clinically, using the Positive and Negative Syndrome Scale (PANSS): at baseline and then at weekly intervals. Plasma and CSF levels of quetiapine and norquetiapine as well CSF 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindole-acetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were obtained at baseline and again after at least a 4 week medication trai…

AdultMalemedicine.medical_specialtyDibenzothiazepinesFluorine RadioisotopesPyrrolidinesmedicine.drug_classCaudate nucleusAtypical antipsychoticPilot ProjectsTritiumMethoxyhydroxyphenylglycolchemistry.chemical_compoundQuetiapine FumarateYoung AdultInternal medicinemedicineHumansBiogenic MonoaminesBiological PsychiatryTemporal cortexFirst episodeBrain Mappingbusiness.industryReceptors Dopamine D2Homovanillic acidHomovanillic AcidMiddle AgedMagnetic Resonance ImagingPsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyFallypridechemistryPositron-Emission TomographyBenzamidesSchizophreniaQuetiapine34-Dihydroxyphenylacetic Acidbusinessmedicine.drugAntipsychotic AgentsProtein BindingJournal of psychiatric research
researchProduct

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.

2005

Amisulpride is a clinically effective antipsychotic drug in a broad dose range with low propensity for extrapyramidal symptoms (EPS). Daily doses and plasma levels of amisulpride were analyzed within a large-scale therapeutic drug monitoring (TDM) survey to find plasma level ranges for optimized treatment under naturalistic conditions. Data of 378 schizophrenic patients treated with amisulpride (100-1550 mg) were included (40% female). Amisulpride plasma levels were analyzed at steady state; assessment comprised improvement (CGI-I) and side-effects, particularly EPS. For detection of cut-off values regarding non-response or EPS, receiver operating characteristics (ROC) curves were applied a…

AdultMalemedicine.medical_specialtyDyskinesia Drug-InducedAdolescentmedicine.drug_classStatistics as TopicAtypical antipsychoticPharmacologyGastroenterologyExtrapyramidal symptomsInternal medicineGermanymedicineHumansAmisulprideBiological PsychiatryAgedRetrospective StudiesAged 80 and overNeurologic ExaminationPsychiatric Status Rating ScalesReceiver operating characteristicmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryDopamine antagonistMiddle Agedmedicine.diseasePsychiatry and Mental healthDose–response relationshipROC CurveSchizophreniaTherapeutic drug monitoringSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridebusinessmedicine.drugAntipsychotic AgentsJournal of psychiatric research
researchProduct

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclo…

2008

To elucidate the Batypicality( of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. ( 18 F)fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel ( 11 C)raclopride-PET stu…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesPyrrolidinesTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyBinding CompetitiveBasal GangliaPiperazinesYoung AdultDopamine receptor D3Internal medicinemedicineHaloperidolHumansPharmacology (medical)ZiprasidoneCarbon RadioisotopesTemporal cortexRacloprideDose-Response Relationship DrugChemistryReceptors Dopamine D2Dopamine antagonistReceptors Dopamine D3Psychiatry and Mental healthThiazolesEndocrinologyFallyprideRaclopridePositron-Emission TomographyBenzamidesSchizophreniaDopamine AntagonistsFemaleRadiopharmaceuticalsmedicine.drugAntipsychotic AgentsJournal of clinical psychopharmacology
researchProduct

Benign and Atypical Meningioma Metabolic Signatures by High-Resolution Magic-Angle Spinning Molecular Profiling

2008

Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15%-20% of CNS tumors. The WHO classifies meningiomas into three histological grades: benign, atypical, and anaplasic in accordance with the clinical prognosis. Atypical and anaplasic meningiomas tend to recur. Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma. In this context, high-resolution magic-angle spinning (HR-MAS) spectroscopy of intact tissue from brain tumor biopsies has shown great potential as a support diagnostic tool. In this work, we show differences between benign and atypical meningioma…

AdultMalemedicine.medical_specialtyPathologyMagnetic Resonance SpectroscopyBrain tumorHigh resolutionBiologyMalignancyBiochemistryMeningiomaInternal medicineBiomarkers TumorMeningeal Neoplasmsotorhinolaryngologic diseasesmedicineHumansneoplasmsAgedAged 80 and overPrincipal Component AnalysisGene Expression ProfilingAtypical meningiomaGeneral ChemistryMiddle Agedmedicine.diseaseSpinal cordnervous system diseasesGene expression profilingEndocrinologymedicine.anatomical_structureBenign MeningiomaFemaleMeningiomaJournal of Proteome Research
researchProduct

Attitude towards adherence in patients with schizophrenia at discharge

2009

Abstract Background Purpose of the present study was to assess the attitude towards adherence at discharge and to verify its predictability using anamnestic and sociodemographic variables, factors influencing clinical treatment as well as the medical treatment applied. Methods Attitude towards adherence was evaluated in 369 inpatients with schizophrenic spectrum disorders within a naturalistic multicenter trial using the Compliance Rating Scale (CRS) by Kemp. Biweekly ratings of the PANSS, UKU and the Subjective Well-being under Neuroleptic Treatment Scale (SWN-K) were applied. Logistic regression and CART analyses were used to determine significant predictor variables for the attitude towa…

AdultMalemedicine.medical_specialtyPsychosisTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticLogistic regressionStatistics NonparametricMedication Adherence03 medical and health sciences0302 clinical medicineRating scaleSurveys and QuestionnairesMulticenter trialmedicinePsychoeducationHumansPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePatient Discharge3. Good health030227 psychiatryPsychiatry and Mental healthSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyPsychologyAttitude to Health030217 neurology & neurosurgeryFollow-Up StudiesClinical psychologyPsychopathologyJournal of Psychiatric Research
researchProduct

Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

1999

Rationale: EMD 57445 (panamesine) is a high affinity sigma ligand with the profile of an atypical antipsychotic in animal studies. It has been reported recently to have antipsychotic activity in schizophrenia. However, its metabolite, EMD 59983, binds also to D2 and D3 dopamine (DA) receptors. Objectives: The aim of this study was to test, using single photon emission computed tomography (SPECT) and [123I]iodobenzamide (IBZM) as the radiotracer, whether EMD 59983 would pass the blood-brain barrier and to what extent it would contribute to the effects of EMD 57445 in schizophrenia. Methods: Two IBZM SPECT-scans were performed in five neuroleptic-free schizophrenic patients (DSM IV), one befo…

AdultMalemedicine.medical_specialtyPyrrolidinesmedicine.drug_classmedicine.medical_treatmentSigma receptorAtypical antipsychoticPanamesinePharmacologychemistry.chemical_compoundIodobenzamidePiperidinesDopamine receptor D3DopamineInternal medicinemedicineHumansReceptors sigmaAntipsychoticOxazolesTomography Emission-Computed Single-PhotonPharmacologyReceptors Dopamine D2Middle AgedCorpus StriatumPyrimidinesEndocrinologychemistryBlood-Brain BarrierDopamine receptorBenzamidesSchizophreniaFemaleAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.

2008

Abstract Because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. In a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (CGI) and side effects (UKU) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 ± 14.2 years, range 18–83 years) under amisulpride therapy. Mean amisulpride doses (574 ± 269 mg/day), plasma levels (304 ± 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 ± 0.41 ng/mL:mg), clinical respons…

AdultMalemedicine.medical_specialtySide effectAdolescentmedicine.drug_classPoison controlAtypical antipsychoticSchizoaffective disorderComorbidityGastroenterologyYoung AdultExtrapyramidal symptomsInternal medicinemedicineHumansPharmacology (medical)AmisulpridePsychiatryAgedPharmacologyAged 80 and overDose-Response Relationship DrugDopamine antagonistAge FactorsMiddle Agedmedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridePsychologymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.

2006

INTRODUCTION: It is assumed that female and male schizophrenic patients respond differentially to acute and chronic treatment with antipsychotics because of pharmacokinetic and pharmacodynamic factors linked to hormonal and constitutional gender differences. However, to date no empirical evidence exists in support of this notion. METHODS: In a naturalistic clinical study, we investigated gender differences in a sample of schizophrenic inpatients with acute exacerbation treated with the atypical antipsychotic amisulpride, a selective dopamine D2/D3 receptor antagonist with proven antipsychotic efficacy. Prescribed amisulpride dose, plasma level, clinical response (CGI), and side effects (UKU…

AdultMalemedicine.medical_specialtySide effectExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPharmacologyDrug Administration ScheduleSex FactorsInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticmedicine.diagnostic_testGeneral MedicineDrug ToleranceHospitalizationPsychiatry and Mental healthTherapeutic drug monitoringPharmacodynamicsSchizophreniaFemaleAmisulprideDrug MonitoringSulpiridePsychologySulpiridemedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis

1980

In 21 patients who had undergone total pancreatectomy for pancreatic head carcinoma, the uninvolved pancreas was examined with regard to the type, incidence and regional distribution of duct epithelial proliferation. The results were compared with those in 37 operative specimens from patients with chronic pancreatitis, in 46 normal pancreases from autopsies and with findings in experimental pancreatic carcinogenesis. While the incidence of squamous metaplasia and non-papillary epithelial hypertrophy varied little in the different groups, papillary epithelial hyperplasia was found three times more often in cases of carcinoma, with associated mild duct obstruction. Atypical epithelial prolife…

Adultmedicine.medical_specialtyNitrosaminesHistologyGastroenterologyPathology and Forensic MedicinePancreatectomyCricetinaeInternal medicineCarcinomamedicineAnimalsHumansMolecular BiologyPancreatic ductAtypical small acinar proliferationHyperplasiamedicine.diagnostic_testbusiness.industryPancreatic DuctsCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseSquamous metaplasiaPancreatic Neoplasmsmedicine.anatomical_structurePancreatitisChronic DiseasePancreatitisFemaleCA19-9AnatomyPancreasbusinessDuct (anatomy)Virchows Archiv A Pathological Anatomy and Histology
researchProduct